Market Overview

Needham Incrementally Bullish On Cara Therapeutics After CR845 Meets Endpoints

Needham Incrementally Bullish On Cara Therapeutics After CR845 Meets Endpoints

Cara Therapeutics Inc (NASDAQ: CARA) stock spiked 34 percent Wednesday after the company reported that a Phase 2/3 trial for intravenous CR845 met primary and secondary endpoints.

The investor bullishness resonated with Needham. 

The Rating

Needham analyst Alan Carr maintained a Buy rating on Cara and raised the price target from $23 to $28.

The Thesis

Although Cara’s high dose met primary endpoints for pain relief, the low dose missed statistical significance. Nonetheless, the analyst regards the profile of the post-surgery pain reliever, including low addictive qualities and low rates of nausea and vomiting, as “attractive.” (See Carr's track record here.) 

Carr expects Cara will need to complete another Phase 3 trial in post-surgical pain before securing regulatory approval for the candidate, but the positive Phase 2/3 results are seen to reduce program risk.

Needham predicts the follow-up trial will begin in early 2019 with commercial launch in the second half of 2021. It also anticipates Phase 3 trial results for intravenous CR845 in uremic pruritus — an indication seen to be Cara’s strategic priority — in the first half of 2019.

Price Action

Cara shares were trading up 1 percent at $18.24 at the time of publication Thursday morning. 

Related Links:

Cara Therapeutics Shares Jump On Licensing Deal For Pruritis Treatment

Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Latest Ratings for CARA

May 2020Cantor FitzgeraldReiteratesOverweight
Apr 2020WedbushMaintainsOutperform
Apr 2020Cantor FitzgeraldReiteratesOverweight

View More Analyst Ratings for CARA
View the Latest Analyst Ratings


Related Articles (CARA)

View Comments and Join the Discussion!

Posted-In: Alan Carr Joseph StringerAnalyst Color Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga

Latest Ratings

WHRCredit SuisseMaintains162.0
TCredit SuisseMaintains31.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at